Insight Molecular Diagnostics Inc. Common Stock IMDX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.3%-5.7pp | 57%+1.7pp | 55.2%— | —— | —— | |
| Operating margin | -2,500.7%-1,240pp | -1,260.8%+132pp | -1,392.9%+105pp | -1,498.3%+25.8pp | -1,524.1%+1,721pp | |
| Net margin | -2,454.6%-1,216pp | -1,238.5%+142pp | -1,380.7%+109pp | -1,489.7%+24.9pp | -1,514.6%+1,710pp | |
| Efficiency | ||||||
| Asset turnover | 0×-0.1× | 0.1×+0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.5×+1.3× | 1.3×-1.5× | 2.8×-1.2× | 4×+0.3× | 3.7×+2.1× | |
| Per Share | ||||||
| Book value per share | -$0.31+70.0% | -$1.03-260% | -$0.29-937% | $0.03-91.4% | $0.40+142% | |
| Valuation | ||||||
| Market capitalization | $185.35M+92.3% | —— | —— | —— | —— | |
| Price / sales | 95.1×+72.5× | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) runs a 51.3% gross margin and a -2500.7% operating margin, with a -2454.6% net margin.
- Where do Insight Molecular Diagnostics Inc. Common Stock's ratios come from?
- Every ratio is computed from Insight Molecular Diagnostics Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
